Overview

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of QL1706 and Olaparib in human epidermal growth factor receptor 2 (HER2)-negative unresectable and/or metastatic breast cancer who had received 2-4 line of prior systematic therapy.

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

olaparib